Abbott Laboratories (NYSE:ABT) Shares Sold by Piscataqua Savings Bank

Piscataqua Savings Bank lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 1.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 7,383 shares of the healthcare product maker’s stock after selling 87 shares during the quarter. Piscataqua Savings Bank’s holdings in Abbott Laboratories were worth $835,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABT. Scientech Research LLC acquired a new position in Abbott Laboratories during the 2nd quarter worth approximately $384,000. Kathmere Capital Management LLC boosted its position in Abbott Laboratories by 48.0% in the 2nd quarter. Kathmere Capital Management LLC now owns 4,315 shares of the healthcare product maker’s stock valued at $448,000 after buying an additional 1,399 shares during the last quarter. Ascent Group LLC increased its position in shares of Abbott Laboratories by 13.8% during the second quarter. Ascent Group LLC now owns 21,772 shares of the healthcare product maker’s stock worth $2,262,000 after acquiring an additional 2,639 shares during the last quarter. Annandale Capital LLC boosted its holdings in Abbott Laboratories by 1,125.5% in the second quarter. Annandale Capital LLC now owns 33,124 shares of the healthcare product maker’s stock valued at $3,442,000 after purchasing an additional 30,421 shares during the last quarter. Finally, Copperwynd Financial LLC increased its holdings in Abbott Laboratories by 36.0% during the 2nd quarter. Copperwynd Financial LLC now owns 8,620 shares of the healthcare product maker’s stock worth $913,000 after purchasing an additional 2,282 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $125.12 on Monday. The business has a 50 day moving average price of $115.26 and a 200 day moving average price of $113.46. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $125.67. The company has a market cap of $217.01 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 2.51 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting the consensus estimate of $1.34. The firm had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $11,029,400 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.19 earnings per share. Research analysts predict that Abbott Laboratories will post 5.15 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.89%. Abbott Laboratories’s dividend payout ratio is 30.85%.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of research analyst reports. UBS Group lifted their price target on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research note on Thursday. Wells Fargo & Company lifted their price target on Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday. Sanford C. Bernstein lifted their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Stifel Nicolaus raised their target price on Abbott Laboratories from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Mizuho boosted their price objective on Abbott Laboratories from $115.00 to $130.00 and gave the stock a “neutral” rating in a research note on Thursday, October 17th. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $133.06.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.